Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.47% | -20.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.84% | -13.10% | |||
| Operating Income | 16.84% | 13.10% | |||
| Income Before Tax | 17.03% | 13.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.03% | 13.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.03% | 13.35% | |||
| EBIT | 16.84% | 13.10% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 17.07% | 13.33% | |||
| Normalized Basic EPS | 16.93% | 13.31% | |||
| EPS Diluted | 17.07% | 13.33% | |||
| Normalized Diluted EPS | 16.93% | 13.31% | |||
| Average Basic Shares Outstanding | 0.03% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
